Patents Issued in June 24, 2021
  • BRAIN HEALTH FOOD OR BRAIN HEALTH BEVERAGE, AND METHOD FOR ADMINISTERING SAME
    Publication number: 20210186971
    Abstract: [Problems to be solved] To develop a food or beverage for health of brain, for preventing and alleviating brain atrophy due to alcohol intake. [Means for Solving Problems] This invention relates to a food or beverage for health of brain containing folic acid, vitamin B6 and vitamin B12 as active ingredients for preventing decrease of brain volume due to drinking of alcohol by habitual drinkers who are not suffering from dementia, i.e., healthy people, wherein the food or beverage for health of brain contains 0.4-0.8 mg of folic acid, 10-20 mg of vitamin B6 and 0.25-0.5 mg of vitamin B12.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 24, 2021
    Inventor: Kaechang PARK
  • FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS
    Publication number: 20210186972
    Abstract: Disclosed are pharmaceutical formulations comprising a compound of formula (I): in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 15, 2019
    Publication date: June 24, 2021
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Kansas, Northwestern University
    Inventors: Udo Rudloff, Serguei Kozlov, Juan Jose Marugan, Sui Huang, Samarjit Patnaik, John C. Braisted, Noel T. Southall, Marc Ferrer, Christopher Dextras, John Haslam, Michael Baltezor
  • COMBINATION OF RIBOCICLIB AND DABRAFENIB FOR TREATING OR PREVENTING CANCER
    Publication number: 20210186973
    Abstract: The present disclosure relates to pharmaceutical combinations comprising a cyclin dependent kinase 4/6 (CDdK4/6) inhibitor compound, (b) a B-Raf inhibitor compound, and optionally (c) an aipha-isoform specific phosphatidylinositol 3-kinase (P13K) inhibitor compound, for the treatment or prevention of cancer, as well as related pharmaceutical compositions, uses, and methods of treatment or prevention of cancer.
    Type: Application
    Filed: October 19, 2020
    Publication date: June 24, 2021
    Inventors: Giordano CAPONIGRO, Thomas HORN-SPIROHN, Joseph LEHAR
  • ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH
    Publication number: 20210186974
    Abstract: Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 4, 2020
    Publication date: June 24, 2021
    Applicant: Pfizer Inc.
    Inventor: Steven Martin Evans
  • NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE
    Publication number: 20210186975
    Abstract: The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeutics to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the symptoms of such diseases and therefore represent a new treatment modality for ameliorating chronic and acute conditions. The compounds of the invention are capable of selectively potentiating the activity of the Nurr1:RXR? heterodimer, and are able to treat diseases or conditions associated with aberrant Nurr1:RXR? function. The invention further provides methods for treating neurodegenerative disorders by administration of Nurr1:RXR? activating agents.
    Type: Application
    Filed: December 30, 2020
    Publication date: June 24, 2021
    Inventors: Demetrios K. VASSILATIS, Athanasios D. Spathis, Demesthenes Fokas
  • METHODS AND COMPOSITIONS FOR TREATMENT OF ZIKA VIRUS INFECTION
    Publication number: 20210186976
    Abstract: The present disclosure is directed to methods and compositions that are useful in combating the spread of Zika virus infections, such as, but not limited to, methods and compositions for treating, preventing or suppressing a Zika virus infection in a subject. The methods comprise administering to the subject an effective amount of a compound of the disclosure, or a composition (such as a pharmaceutical composition) comprising a compound of the disclosure.
    Type: Application
    Filed: March 1, 2021
    Publication date: June 24, 2021
    Inventors: Yarlagadda S. BABU, Pravin L. KOTIAN, Shanta BANTIA
  • MEDICAL USES
    Publication number: 20210186977
    Abstract: The present invention relates generally to anti-viral agents for use in preventing herpes virus reactivation in a patient, wherein the patient has received a therapy comprising natural killer (NK) cells and/or NK-like T cells. Additionally, the invention relates to NK cells and/or NK-like T cells for use in treating a malignant disease in a patient, wherein the use comprises the step of administering an anti-viral agent to the patient with the NK cell and/or NK-like T cell therapy. The invention also relates to pharmaceutical compositions and kits.
    Type: Application
    Filed: April 30, 2019
    Publication date: June 24, 2021
    Inventors: Hareth Nahi, Carl Arnold Gosta Gahrton, Evren Alici, Hans-Gustaf Einar Ljunggren
  • COMBINATION THERAPY
    Publication number: 20210186978
    Abstract: The invention generally relates to a combination therapy for treating cancer comprising administering at least two distinct therapeutic agents. Components of the combination therapy and methods of using the combination therapy are provided.
    Type: Application
    Filed: May 31, 2019
    Publication date: June 24, 2021
    Inventors: Kerry WHALEN, Samantha PERINO, Richard WOOSTER, Sudhakar KADIYALA, James M. QUINN
  • SMALL MOLECULE INHIBITORS OF CDK12/CDK13
    Publication number: 20210186979
    Abstract: The invention provides compounds and methods of inhibiting a cyclin-dependent kinase, comprising contacting the cyclin-dependent kinase and an effective amount or concentration of a compound of formula (I) wherein variables are as defined herein. Compounds of formula (I) can be highly selective inhibitors of cyclin-dependent kinases such as CDK12/13, relative to other kinases such as casein kinases, such as CK1?/?. Compounds can be used in treatment of cancers, such as breast cancer, brain cancer and ovarian cancer.
    Type: Application
    Filed: May 7, 2019
    Publication date: June 24, 2021
    Inventors: William R. Roush, Derek R. Duckett, Andrii Monastyrskyi
  • COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR
    Publication number: 20210186980
    Abstract: Provided is a use of the prophylaxis, amelioration or therapy of intractable epilepsy, for example, Focal Cortical Dysplasia (FCD).
    Type: Application
    Filed: February 9, 2021
    Publication date: June 24, 2021
    Inventors: Jeong Ho LEE, Jae Seok LIM, Woo-ll KIM, Dong Seok KIM, Hoon Chul KANG, Se Hoon KIM
  • METHODS OF USE OF EMULSION FORMULATIONS OF APREPITANT
    Publication number: 20210186981
    Abstract: Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
    Type: Application
    Filed: March 5, 2021
    Publication date: June 24, 2021
    Inventors: Thomas B. Ottoboni, Han Han
  • METHODS AND COMPOSITIONS FOR TREATING MELANOMA
    Publication number: 20210186982
    Abstract: The present invention relates to a method and composition for treating melanoma. More particularly, inventors have shown that high expression of USP14 correlates with melanoma progression and with a poorer survival rate in metastatic melanoma patients. Then, they have shown that an inhibition of ubiquitin-specific peptidase 14 (USP14) by siRNAs and pharmacological inhibitors (b-AP15, WP1130 and HBX41108), the cell proliferation of melanoma cell drastically decreased. They have also shown that melanoma treatment with pharmacological inhibitors can overcome resistance to drugs targeting oncogenic BRAF. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from melanoma by quantifying the expression level of USP14 in a biological sample and to a method of treating melanoma and resistant melanoma by using the inhibitors of USP14.
    Type: Application
    Filed: March 23, 2018
    Publication date: June 24, 2021
    Inventors: Marcel DECKERT, Sophie TARTARE - DECKERT, Aude MALLAVIALLE, Robin DIDIER
  • ORALLY ADMINISTERED COMBINATIONS OF AMOXICILLIN AND AVIBACTAM DERIVATIVES FOR TREATING MYCOBACTERIAL INFECTIONS
    Publication number: 20210186983
    Abstract: Pharmaceutical compositions comprise amoxicillin and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions. The pharmaceutical compositions can be formulated for oral administration and following oral administration provide a therapeutically effective amount of amoxicillin and avibactam in the plasma of a patient. The oral pharmaceutical compositions and methods can be used to treat mycobacterial infections.
    Type: Application
    Filed: December 16, 2020
    Publication date: June 24, 2021
    Applicant: Arixa Pharmaceuticals, Inc.
    Inventor: JOAQUIM TRIAS
  • CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING ANCA ASSOCIATED VASCULITIDES
    Publication number: 20210186984
    Abstract: The present disclosure relates to methods for treating an ANCA associated vasculitis, for example, granulomatosis with polyangiitis (GPA), with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, that inhibit dipeptidyl peptidase 1 (DPP1) activity. In one embodiment, the compound of Formula (I) is (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (INS1007).
    Type: Application
    Filed: January 25, 2021
    Publication date: June 24, 2021
    Inventors: Keith DIPETRILLO, Carlos FERNANDEZ, Jimin ZHANG
  • METHODS FOR TREATING DISEASES ASSOCIATED WITH CILIOPATHIES
    Publication number: 20210186985
    Abstract: Methods of treating a ciliopathy-associated disease are disclosed, including administering to a subject in need thereof an effective amount of a compound that targets at least one G-protein coupled receptor. Methods for identifying therapeutic agents for treating a disease having a ciliopathy are provided, including providing an animal model system of the ciliopathy for testing a putative therapeutic agent; administering a disruptive agent to the animal, treating the administered animal with the putative therapeutic agent, comparing the measurable phenotype of the treated animal with that of the animal without treatment, and identifying the therapeutic target for treating a ciliopathy, when the measurable phenotype of the treated animal is reduced as compared with that of the animal without treatment.
    Type: Application
    Filed: October 12, 2018
    Publication date: June 24, 2021
    Inventors: Sophie SAUNIER, Luis BRISENO-ROA, Soraya SIN-MONNOT, Jean-philippe ANNEREAU, Marion DELOUS, Hugo GARCIA, Guillermo DEL ANGEL, Flora LEGENDRE
  • USES OF CELASTROL IN PREVENTING AND/OR TREATING CHOLESTATIC LIVER DISEASE AND LIVER FIBROSIS
    Publication number: 20210186986
    Abstract: The present disclosure relates to a celastrol or a pharmaceutically acceptable salt thereof, and a use thereof in the manufacture of a medicament for preventing and/or treating a cholestatic liver disease or a liver fibrosis.
    Type: Application
    Filed: March 9, 2018
    Publication date: June 24, 2021
    Applicants: KUNMING INSTITUTE OF BOTANY,THE CHINESE ACADEMY OF SCIENCES, ZHEJIANG CHONGLING TECHNOLOGY CO., LTD.
    Inventors: Fei Li, Qi Zhao
  • GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
    Publication number: 20210186987
    Abstract: This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 24, 2021
    Inventors: David CZEKAI, Maciej GASIOR, Lorianne MASUOKA, Julia TSAI, Joseph HULIHAN, Alex AIMETTI
  • PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
    Publication number: 20210186988
    Abstract: Embodiments of the present invention are directed to a plurality of substantially spherical microspheres comprising at least one API substantially dispersed in at least one polymer and a lyoprotectant on an outside surface of the plurality of substantially spherical microspheres, wherein the plurality of substantially spherical microspheres have a D99[num] particle diameter of less than about 10 ?m; a D90[num] circularity value of from about 0.8 to about 1.0; and comprise API in a weight of about 20 to about 40 wt. % of the polymer. Other embodiments relate to injectable compositions comprising such microspheres and methods of treating a number of conditions by administering such injectable compositions to a subject.
    Type: Application
    Filed: December 23, 2020
    Publication date: June 24, 2021
    Inventors: Jeffrey Missling, Emily R. Rolfes Meyering, Henry Meyer, Celeste Ondich
  • ENHANCED TRAINED IMMUNITY IN MYELOID CELLS BY SHIP-1 INHIBITION
    Publication number: 20210186989
    Abstract: The present invention refers to the medical field. Particularly, it refers to SHIP-1 inhibitors for use in enhancing the non-specific response of trained innate immune cells (i.e. enhancing the training of the innate immune cells) in a subject, wherein the SHIP-1 inhibitor is administered before, after or simultaneously to a treatment with a stimulus responsible for training the innate immune cells.
    Type: Application
    Filed: June 6, 2019
    Publication date: June 24, 2021
    Inventors: David SANCHO MADRID, Paula SAZ LEAL, Carlos DE FRESNO SÁNCHEZ, John CHISHOLM, William KERR
  • METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS
    Publication number: 20210186990
    Abstract: Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS di,sease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.
    Type: Application
    Filed: August 28, 2020
    Publication date: June 24, 2021
    Inventors: Joshua Cohen, Justin Klee
  • TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS
    Publication number: 20210186991
    Abstract: Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.
    Type: Application
    Filed: March 2, 2021
    Publication date: June 24, 2021
    Inventor: Stanley L. Hazen
  • METHOD AND COMPOSITIONS FOR THE TREATMENT OF ANEMIA THROUGH THE INHIBITION OF FURIN
    Publication number: 20210186992
    Abstract: Methods and compositions that can be used to modulate the activity of furin in a subject are disclosed herein. In some embodiments, the methods include administering a pharmaceutical composition including a protease inhibitor. In some embodiments, the protease inhibitor inhibits furin activity by binding to the catalytic site, the allosteric site, or both.
    Type: Application
    Filed: February 21, 2017
    Publication date: June 24, 2021
    Inventors: Richard K. Watt, Chad Hancock
  • COMBINATION THERAPIES TARGETING MITOCHONDRIA FOR CANCER THERAPY
    Publication number: 20210186993
    Abstract: Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment, the composition comprises Gamitrinib and a PI3K inhibitor selected from PX-866, AZD6482, LY294002, BEZ235, GSK458, GDC0941, ZSTK474, BKM120 and GSK2636771B. Methods of treating cancer are also provided.
    Type: Application
    Filed: August 7, 2020
    Publication date: June 24, 2021
    Inventors: Dario C. Altieri, Jagadish C. Ghosh
  • Pharmaceutical formulations comprising 5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine
    Publication number: 20210186994
    Abstract: This invention relates to a pharmaceutical composition comprising 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine as the active pharmaceutical ingredient, and therapeutic uses of the pharmaceutical formulation. In particular, the invention is directed to tablets comprising the pharmaceutical composition, methods of preparing the tablets, and therapeutic uses thereof.
    Type: Application
    Filed: March 5, 2021
    Publication date: June 24, 2021
    Inventors: Dauntel S. Verwijs, Samir Desai, Pradeep K. Sharma, Leonard W. Rozamus, Jeff Williamson, Danica Cartwright, Parag Ved
  • PLASMALOGEN-CONTAINING COMPOSITION
    Publication number: 20210186995
    Abstract: This invention provides a technique that is capable of stably storing plasmalogen for a long period of time. More specifically, the invention provides a plasmalogen-containing solid composition comprising plasmalogen, ?-cyclodextrin, and a pH alkali adjusting agent, and having a pH of 6 to 8 when formed into a 1 mass % aqueous suspension.
    Type: Application
    Filed: July 4, 2019
    Publication date: June 24, 2021
    Applicant: MARUDAI FOOD CO., LTD.
    Inventors: Jun KAWAMURA, Hitomi KIMURA, Rihoko NAKASE, Satoshi KOTOURA
  • METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS
    Publication number: 20210186996
    Abstract: Provided herein are methods and compositions related to treating and/or preventing multiple sclerosis in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.
    Type: Application
    Filed: November 30, 2018
    Publication date: June 24, 2021
    Inventors: Eric Marcotulli, Dan Alminana, Mark Morris, Ryan Dellinger
  • METHODS AND COMPOSITIONS FOR INCREASING NAD LEVEL IN MAMMALS WITH D-RIBOSE AND VITAMIN B3
    Publication number: 20210186997
    Abstract: Methods and compositions for increasing NAD levels in mammals by administering to the mammal an effective amount of D-ribose or D-ribose with Vitamin B3, where the Vitamin B3 may be niacin, nicotinamide, nicotinamide riboside or nicotinamide mononucleotide. The ratio between D-ribose and Vitamin B3 could vary between 0.5:10 and 10:0.5. The timing of administration to the mammal is at a time when the mammal is active or about to be active, whether the mammal is diurnal or nocturnal.
    Type: Application
    Filed: May 10, 2019
    Publication date: June 24, 2021
    Inventor: Yongquan Xue
  • COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS
    Publication number: 20210186998
    Abstract: Described herein are methods and compositions for the treatment of skin conditions associated the dysbiosis. Further described herein is the use of metabolites for treatment of dysregulated microbiota in a subject. Such metabolites can be produced by microorganisms present in a higher abundance in the skin of healthy subjects as compared to the skin of a subject having dysbiosis of the skin. In addition, compositions and methods provided herein describe the use of metabolites as part of a combination therapy.
    Type: Application
    Filed: February 25, 2021
    Publication date: June 24, 2021
    Inventor: Paul WAGNER
  • METHOD FOR TREATMENT OF CANCER
    Publication number: 20210186999
    Abstract: A method of treating cancer is provided wherein the method comprises inhibiting or reducing sialylation of specifically Mesenchymal Stromal Cells (MSCs) to inhibit MSC immunosuppression and restore T cell proliferation in cancer. The method may comprise administering a sialyltransferase inhibitor (e.g. 3Fax-Peracetyl Neu5Ac) or sialidase. Also described is administration of MSCs which have been manipulated prior to administration to remove sialic acids and use of a small molecule or blocking antibody which blocks interactions between MSC-sialic acid and lectins, such as Siglec 7, and/or blocks interactions between MSC-lectins and sialic acid.
    Type: Application
    Filed: October 31, 2018
    Publication date: June 24, 2021
    Inventors: Michael O'Dwyer, Thomas Ritter, Aideen Ryan, Kevin Lynch
  • METHODS FOR TREATING DEGENERATIVE DISC DISEASE AND CHRONIC LOWER BACK PAIN
    Publication number: 20210187000
    Abstract: The present invention in various aspects and embodiments provides methods for the treatment or prevention of degenerative disc disease or chronic lower back pain.
    Type: Application
    Filed: March 8, 2021
    Publication date: June 24, 2021
    Inventors: Ondrej SLABY, Manu CAPOOR
  • Compositions and Devices for Systemic Delivery of Uridine
    Publication number: 20210187001
    Abstract: A solution of uridine in saline, and optionally also containing beta-hydroxybutyrate, can be administered subcutaneously. A reservoir capable of holding a uridine solution in saline is described, the reservoir being fluidically linked to one or more infusion needles, and a pump configured to move the solution from the reservoir through the one or more infusion needles into a subject.
    Type: Application
    Filed: February 1, 2019
    Publication date: June 24, 2021
    Inventors: Reid W. VON BORSTEL, Rolando Alejandro GARCIA GARCIA
  • ANTIMALARIAL DRUG, MALARIA TREATMENT METHOD, SCREENING METHOD FOR CANDIDATE SUBSTANCE FOR MALARIA TREATMENT, MALARIA SEVERITY MARKER, METHOD FOR TESTING RISK OF SEVERE MALARIA, AND TEST REAGENT
    Publication number: 20210187002
    Abstract: The present invention provides a new antimalarial drug. The antimalarial drug of the present invention includes: a binding inhibitor that inhibits binding between a RIFIN protein and a leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) protein; an inducer of the binding inhibitor; or an expression inhibitor of RIFIN or LILRB1.
    Type: Application
    Filed: November 28, 2018
    Publication date: June 24, 2021
    Inventors: Hisashi ARASE, Fumiji HIRAYASU, Kouyuki HIRAYASU
  • EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
    Publication number: 20210187003
    Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
    Type: Application
    Filed: July 28, 2020
    Publication date: June 24, 2021
    Inventors: Diane Elizabeth FRANK, Richard K. BESTWICK
  • DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY ASSOCIATED WITH IMMUNODEPLETION
    Publication number: 20210187004
    Abstract: The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and/or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and/or neurotoxicity.
    Type: Application
    Filed: April 12, 2019
    Publication date: June 24, 2021
    Inventors: Sarah McMAHON, Yasuhiro OKI
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20210187005
    Abstract: A pharmaceutical composition includes polymer units ? and ?, each having a hydrophilic polymer chain bound to a cationic polymer chain, and a drug. The polymer units ? and ? are radially arranged such that the cationic polymer chains are directed inward and the hydrophilic polymer chains are directed outward, thereby forming a micelle with the drug encapsulated in the micelle. The cationic polymer chain of the polymer unit ? has a phenylboronic acid group in a side chain, and the cationic polymer chain of the polymer unit ? has a phenylboronic acid binding site in a side chain. The phenylboronic acid group and the phenylboronic acid binding site form a cross-linked structure that can dissociate in an acidic environment and/or in the presence of a substance capable of competitive binding.
    Type: Application
    Filed: February 16, 2021
    Publication date: June 24, 2021
    Applicant: KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION
    Inventors: Kazunori KATAOKA, Takehiko ISHII, Mitsuru NAITO, Naoto YOSHINAGA, Taisuke ENDO
  • TALEN-BASED GENE CORRECTION
    Publication number: 20210187006
    Abstract: The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.
    Type: Application
    Filed: March 4, 2021
    Publication date: June 24, 2021
    Inventors: Mark Osborn, Jakub Tolar, Bruce Robert Blazar, Daniel Voytas
  • C/EBP ALPHA SARNA COMPOSITIONS AND METHODS OF USE
    Publication number: 20210187007
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 24, 2021
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Saetrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • USE OF ACANTHOPANAX TRIFOLIATUS POLYSACCHARIDE ATP1-1 IN PREPARATION OF DRUGS FOR TREATMENT OF DIABETES
    Publication number: 20210187008
    Abstract: A method of treating diabetes includes the step of preparing Acanthopanax trifoliatus polysaccharide ATP1-1 into drugs for treating the diabetes. The Acanthopanax trifoliatus polysaccharide ATP1-1 can alleviate the symptoms of weight loss in diabetic mice and facilitate the weight increase of mice; ATP1-1 has a hypoglycemic effect on the diabetic mice, and can enhance the ability to control blood glucose, reduce blood glucose fluctuation, and achieve the effect of treating diabetes; ATP1-1 can effectively reverse the decrease of insulin caused by injury of pancreatic islet; ATP1-1 has various degrees of therapeutic effects on mice pancreatic islets and can inhibit apoptosis of pancreatic islet cells; ATP1-1 can effectively repair injury of a spleen and regulate the body's immunologic function.
    Type: Application
    Filed: January 15, 2020
    Publication date: June 24, 2021
    Applicant: GUANGDONG PHARMACEUTICAL UNIVERSITY
    Inventor: Yufang PAN
  • Use of Polysaccharide for Treating ST-Elevation Myocardial Infarction and Diseases of the Digestion System
    Publication number: 20210187009
    Abstract: Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using ?-1,3/1,6-D-glucan derived from mycellium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising ?-1,3/1,6-D-glucan are also provided.
    Type: Application
    Filed: March 8, 2021
    Publication date: June 24, 2021
    Inventors: Peter Sugita, Wiwiek Widyastuti Budiliantono, Aurelia Maxine Sugita
  • POLYMER LUNG SURFACTANTS
    Publication number: 20210187010
    Abstract: Disclosed herein are fully synthetic polymer-based lung surfactant materials, for the first time, as next generation SRT. In vitro studies on these polymer lung surfactants show that the candidate materials effectively mimic the surface tension controlling properties of currently marketed natural lung surfactants. Further, the polymer lung surfactants have strong protein resistance, which makes this class of materials promising also for potential use in Acute Respiratory Distress Syndrome (ARDS) treatment.
    Type: Application
    Filed: November 30, 2020
    Publication date: June 24, 2021
    Applicant: Purdue Research Foundation
    Inventors: You-Yeon Won, Hyun Chang Kim
  • METHOD OF TREATING ACID-BASE DISORDERS
    Publication number: 20210187011
    Abstract: The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
    Type: Application
    Filed: November 3, 2018
    Publication date: June 24, 2021
    Inventors: Gerrit KLAERNER, Jerry M. BUYSSE, Jun SHAO, Dawn Parsell OTTO
  • ANTI-COAGULANT AGENT, ANTICOAGULATION DEVICE, BLOOD COAGULATION CURING METHOD, VASCULAR ENDOTHELIAL CELL FUNCTION IMPROVING METHOD, AND METABOLISM IMPROVING METHOD
    Publication number: 20210187012
    Abstract: An object of the present invention is to provide a method other than the scavenger function against reactive oxygen species for molecular hydrogen to improve life functions, in the fields of medical science, medical care, health industry, agriculture, animal husbandry, and fisheries, and an effect of improving mitochondrial function utilizing the same, and an anticoagulation agent, a blood coagulation curing device, a blood coagulation curing method, and a vascular endothelial cell function improving method. Provided is an anticoagulation agent composed of hydrogen gas or an anticoagulation agent composed of water containing molecular hydrogen. Preferably the anticoagulation agent is such that molecular hydrogen improves mitochondrial function by increasing mitochondrial hydrogenase activity, thereby improving blood clotting.
    Type: Application
    Filed: May 22, 2019
    Publication date: June 24, 2021
    Applicants: H2BANK CO., LTD., ANICOM SPECIALTY MEDICAL INSTITUTE INC.
    Inventors: Toru ISHIBASHI, Genki ISHIHARA
  • Methods of Treating and Preventing Cancer by Disrupting the Binding of Copper in the Map Kinase Pathway
    Publication number: 20210187013
    Abstract: The present disclosure provides methods of treating and/or preventing cancer in a subject comprising administering to the subject a copper-reduced diet by itself or as a supplement along with a regular diet to create a copper-reduced melieu, maintain a reduced-copper melieu, or both, thereby treating and/or preventing the development of the cancer. Methods also comprise further adding a copper chelator, MEK inhibitor, or combinations thereof.
    Type: Application
    Filed: January 8, 2021
    Publication date: June 24, 2021
    Applicant: DUKE UNIVERSITY
    Inventors: Chris M. Counter, Donita C. Brady, Michelle L. Turski, Dennis J. Thiele
  • Methods, Systems And Compositions For The Novel Use of Enterobactin to Treat Iron Deficiency And Related Anemia And Promote Red Blood Cell Production
    Publication number: 20210187014
    Abstract: In one embodiment, the invention relates to the use of ferric enterobactin (Fe Ent), and/or Fe-Ent analogs as a therapeutic agent to treat iron deficiency and anemia. In a preferred embodiment, Fe-Ent and/or Fe-Ent analogs may be delivered to a host organism, such as a human subject to treat an iron-related disease condition or other anemia. In alternative embodiments, delivered to a host organism, such as a human subject to promote production or red blood cells. In such an embodiment, Ent and/or Ent analogs may be delivered to a human subject in need thereof through a pharmaceutical composition or through a genetically engineered bacteria, such as a probiotic organism configured to express Ent.
    Type: Application
    Filed: January 18, 2021
    Publication date: June 24, 2021
    Inventors: Min Han, Bin Qi, Mingxue Cui, Aileen K. Sewell
  • COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES
    Publication number: 20210187015
    Abstract: A method of preventing or treating type 2 diabetes comprising administering a therapeutically effective amount of Zn-enriched zinc.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 24, 2021
    Applicant: Vector Vitale IP LLC
    Inventors: Peter NOVAK, Maxim TEMNIKOV, Oleksandr BALAKIN
  • METHOD OF TREATING NONALCOHOLIC STEATOHEPATITIS
    Publication number: 20210187016
    Abstract: A method for preventing or treating Nonalcoholic steatohepatitis (NASH) comprising administering a prophylactically or therapeutically effective amount of 64Zn-enriched zinc. The 64Zn-enriched zinc is in the form of a 64Zne (64Zn enriched) compound or a 64Zne salt. In certain embodiments, the disclosed compositions contain zinc that is at least 80% 64Zne, at least 90% 64Zne, at least 95% 64Zne, or at least 99% 64Zne, for example, zinc that is 80% 64Zne, 85% 64Zne, 90% 64Zne, 95% 64Zne, 99% 64Zne, or 99.9% 64Zne.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 24, 2021
    Applicant: Vector Vitale IP LLC
    Inventors: Peter NOVAK, Maxim TEMNIKOV, Oleksandr BALAKIN
  • COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF OBESITY
    Publication number: 20210187017
    Abstract: A method for reducing the weight of an overweight or obese subject comprising administering a therapeutically effective amount of a composition comprising 64Zn-enriched zinc. A method for preventing or reducing weight gain comprising administering an effective amount of a composition comprising 64Zn-enriched zinc.
    Type: Application
    Filed: October 6, 2020
    Publication date: June 24, 2021
    Applicant: Vector Vitale IP LLC
    Inventors: Peter NOVAK, Maxim TEMNIKOV, Oleksandr BALAKIN
  • CYTOBIOLOGICS AND THERAPEUTIC USES THEREOF
    Publication number: 20210187018
    Abstract: This disclosure provides, e.g., cytobiologic compositions and methods of use thereof. The cytobiologics can be used, e.g., to deliver a protein or nucleic acid to a target cell.
    Type: Application
    Filed: December 7, 2018
    Publication date: June 24, 2021
    Applicant: FLAGSHIP PIONEERING INNOVATIONS V, INC.
    Inventors: Geoffrey A. von Maltzahn, John Miles Milwid, Jacob Rosenblum Rubens, Michael Travis Mee, Nathan Wilson Stebbins, Molly Krisann Gibson, Neal Francis Gordon, Bo Zhang, Kyle Marvin Trudeau, Brigham Jay Hartley, Tamar Rose Putiri, Kiana Mahdaviani, Jagesh Vijaykumar Shah, Michael Connor, Peter Anthony Jones
  • FOOD FACTOR-BASED FORMULATION, PRODUCTS PRODUCED USING SAID FORMULATION AND METHODS FOR PRODUCING SAME
    Publication number: 20210187019
    Abstract: The present abstract relates to an invention patent application for a food factor-based formulation, products produced therewith and method for producing same, pertaining to the field of products of food and medical-pharmaceutical use, developed for numerous treatments for humans, particularly products which can be recognized or registered by the immune system as an antigen; said formulation comprising a blood or blood fraction derivative combined with phospholipids, preferably phosphatidylcholine in an aqueous or serological solution
    Type: Application
    Filed: September 1, 2016
    Publication date: June 24, 2021
    Inventor: Romeo Bebeachibuli
  • PLASMA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210187020
    Abstract: Provided herein are pathogen-inactivated plasma compositions and methods for treating a disease or condition using pathogen-inactivated plasma compositions.
    Type: Application
    Filed: September 3, 2020
    Publication date: June 24, 2021
    Inventors: Laurence CORASH, Richard BENJAMIN, Elan WEINER